| Involvement of melatonin in autophagy-mediated mouse hepatoma H22 cell survival. | |
| | |
MedLine Citation:
|
PMID: 22222116 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The role of autophagy in cancer is controversial. Melatonin has been linked to several aspects of cancer progression and also to regulation of autophagy. Whether melatonin is involved in an autophagy-induced tumor suppressor mechanism or a cyto-protective mechanism is unknown. Therefore, we investigated the effects of melatonin on autophagy and its upstream regulator. We found that melatonin triggers an autophagic process by enhancing Beclin 1 expression and inducing a conversion of microtubule-associated protein 1 light chain 3(LC3)-I to LC3-II, the protein associated with the autophagosome membrane, in hepatoma H22 tumor-bearing mice. Moreover, melatonin inhibits the phosphorylation of the mammalian target of the rapamycin (mTOR) and Akt. Knockdown of Beclin 1 by either RNA interference or co-treatment with the autophagy inhibitor, 3-methyladenine(3-MA), significantly enhanced the melatonin-induced apoptosis in mouse hepatoma H22 cells. Our data provides the first evidence that melatonin induces protective autophagy that prevents mouse hepatoma H22 cells from undergoing apoptosis. A combination of melatonin with an autophagy inhibitor might be a useful therapeutic strategy for hepatocellular carcinoma. |
| | |
Authors:
|
Chang Liu; Zhiling Jia; Xia Zhang; Jincai Hou; Li Wang; Shuling Hao; Xinjian Ruan; Zhonghe Yu; Yongqiu Zheng |
Related Documents
:
|
19899776 - Quercetin reduces inflammatory pain: inhibition of oxidative stress and cytokine produc... 7599226 - The role of intracellular oxidants in apoptosis. 17180056 - Modulation of the antioxidant defence as a factor in apoptosis. 15855056 - Antioxidant up-regulation and increased nuclear dna protection play key roles in adapta... 11686876 - Immunologists getting nervous: neuropeptides, dendritic cells and t cell activation. 11520246 - Does parkinson's disease have an immunological basis? the evidence and its therapeutic ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-2 |
Journal Detail:
|
Title: International immunopharmacology Volume: - ISSN: 1878-1705 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-6 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100965259 Medline TA: Int Immunopharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011. Published by Elsevier B.V. |
Affiliation:
|
Department of Medical Oncology, The Military General Hospital of Beijing PLA, Beijing, China; Third Military Medical University, Chongqing, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against He...
Next Document: Hypertrophic Cardiomyopathy: Infants, Children, and Adolescents.